Physician profile
David S Henry
NPI 1134146574
$12,607.97
in general payments reported to CMS, 2019-2025
30 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,311 · 2020: $1,814 · 2021: $2,776 · 2022: $2,605 · 2023: $1,357 · 2024: $1,487 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,098 · Education: $4.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,097.93 |
| Education | $4.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,366.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,621.16 | 2019-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $1,600.52 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,268.56 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,189.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $1,141.77 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $740.43 | 2020-2025 | Verquvo, Steglatro, Capvaxive |
| Novartis Pharmaceuticals Corporation | $609.61 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $514.81 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $282.91 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $236.94 | 2023-2024 | Inpefa |
| Hikma Pharmaceuticals USA | $159.24 | 2019-2022 | |
| Exact Sciences Corporation | $99.09 | 2025 | Cologuard Collection Kit |
| Zealand Pharma US, INC. | $82.76 | 2020-2021 | |
| Amgen INC. | $82.62 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $78.72 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $70.69 | 2019-2021 | |
| Horizon Therapeutics Plc | $64.27 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $59.49 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.44 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.03 | 2022 | |
| Eyevance Pharmaceuticals LLC | $43.33 | 2021 | |
| Baxter Healthcare | $42.03 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Lifescan, INC. | $41.73 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.13 | 2019 | |
| Abbott Laboratories | $23.14 | 2021 | |
| Mannkind Corporation | $20.99 | 2020 | |
| Glaxosmithkline, LLC. | $20.62 | 2025 | Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $19.01 | 2021 | |
| Allergan, INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.